For the quarter ending 2025-09-30, AGEN had -$7,998K decrease in cash & cash equivalents over the period. -$14,737K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 63,911 | -56,382 |
| Depreciation and amortization | 3,031 | 6,371 |
| Share-based compensation | 3,242 | 7,067 |
| Non-cash royalty revenue | 29,148 | 48,387 |
| Non-cash interest expense | 12,985 | 25,681 |
| Loss on disposal of assets, net | -7 | -929 |
| Gain from deconsolidation of mink therapeutics, inc | 100,924 | - |
| Unrealized loss on long-term investments | -20,096 | - |
| Gain on lease terminations | 0 | 0 |
| Other, net | 455 | -255 |
| Accounts receivable | -183 | 232 |
| Prepaid expenses | -180 | -980 |
| Accounts payable | 14,134 | 12,706 |
| Deferred revenue | 0 | 1 |
| Accrued liabilities and other current liabilities | 9,205 | 4,230 |
| Other operating assets and liabilities | 11,184 | -941 |
| Net cash used in operating activities | -14,737 | -45,840 |
| Purchases of plant and equipment | 0 | 6 |
| Proceeds from sale of plant and equipment | 76 | 282 |
| Proceeds from sale of long-term investment | 0 | 62 |
| Net cash provided by investing activities | 76 | 338 |
| Net proceeds from sale of equity | 8,965 | 18,560 |
| Net proceeds from sale of subsidiary shares in private placement | 0 | 0 |
| Proceeds from ligand purchase agreement, net of expenses | 0 | 0 |
| Proceeds from employee stock purchases and option exercises | 78 | 44 |
| Proceeds from the issuance of long-term debt, net | 0 | 2,500 |
| Impact to cash resulting from deconsolidation of a subsidiary | 1,682 | - |
| Purchase of treasury shares to satisfy tax withholdings | 0 | 87 |
| Payment of long-term debt | 0 | 2,500 |
| Payment of finance lease obligation | 678 | 3,981 |
| Net cash provided by financing activities | 6,683 | 14,536 |
| Effect of exchange rate changes on cash | -20 | 63 |
| Net decrease in cash, cash equivalents and restricted cash | -7,998 | -30,903 |
| Cash and cash equivalents at beginning of period | 44,071 | - |
| Cash and cash equivalents at end of period | 5,170 | - |
AGENUS INC (AGEN)
AGENUS INC (AGEN)